Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Constitutive activation of KIT receptor tyrosine kinase is critical in the pathogenesis of gastrointestinal stromal tumors. Imatinib mesylate, a selective tyrosine kinase inhibitor, has been shown in preclinical models and preliminary clinical studies to have activity against such tumors. METHODS: We conducted an open-label, randomized, multicenter trial to evaluate the activity of imatinib in patients with advanced gastrointestinal stromal tumor. We assessed antitumor response and the safety and tolerability of the drug. Pharmacokinetics were assessed in a subgroup of patients. RESULTS: A total of 147 patients were randomly assigned to receive 400 mg or 600 mg of imatinib daily. Overall, 79 patients (53.7 percent) had a partial response, 41 patients (27.9 percent) had stable disease, and for technical reasons, response could not be evaluated in 7 patients (4.8 percent). No patient had a complete response to the treatment. The median duration of response had not been reached after a median follow-up of 24 weeks after the onset of response. Early resistance to imatinib was noted in 20 patients (13.6 percent). Therapy was well tolerated, although mild-to-moderate edema, diarrhea, and fatigue were common. Gastrointestinal or intraabdominal hemorrhage occurred in approximately 5 percent of patients. There were no significant differences in toxic effects or response between the two doses. Imatinib was well absorbed, with pharmacokinetics similar to those reported in patients with chronic myeloid leukemia. CONCLUSIONS: Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or metastatic gastrointestinal stromal tumor. Inhibition of the KIT signal-transduction pathway is a promising treatment for advanced gastrointestinal stromal tumors, which resist conventional chemotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Self-citationDiagnosis of gastrointestinal stromal tumors: A consensus approach
Fletcher, C. D. M., Berman, J. J., Corless, C., Gorstein, F., Lasota, J., Longley, B. J., Miettinen, M., O'Leary, T. J., Remotti, H., Rubin, B. P., et al. (2002) · Human Pathology · doi:10.1053/hupa.2002.123545 · Cited by 3,419
Self-citationClinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Self-citationDruker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Self-citationTwo Hundred Gastrointestinal Stromal Tumors: Recurrence Patterns and Prognostic Factors for Survival
DeMatteo, R. P., Lewis, J. J., Leung, D., Mudan, S. S., Woodruff, J. M., & Brennan, M. F. (2000) · Annals of Surgery · doi:10.1097/00000658-200001000-00008 · Cited by 2,554
Joensuu, H., Roberts, P. J., Sarlomo-Rikala, M., Andersson, L. C., Tervahartiala, P., Tuveson, D., Silberman, S. L., Capdeville, R., Dimitrijevic, S., Druker, B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441404 · Cited by 2,037
Self-citationBuchdunger, E., Cioffi, C. L., Law, N., Stover, D., Ohno-Jones, S., Druker, B. J., & Lydon, N. B. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38879-2 · Cited by 1,274
Self-citationvan Oosterom, A. T., Judson, I., Verweij, J., Stroobants, S., di Paola, E. D., Dimitrijevic, S., Martens, M., Webb, A., Sciot, R., Van Glabbeke, M., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06535-7 · Cited by 1,264
Self-citationHeinrich, M. C., Griffith, D. J., Druker, B. J., Wait, C. L., Ott, K. A., & Zigler, A. J. (2000) · Blood · doi:10.1182/blood.v96.3.925 · Cited by 1,071
Self-citation
Research works printed but not linked: 4
- Rubin BP, 2001, Cancer Res, 61, 8118
- Goss GA, 2000, Prog Proc Am Soc Clin Oncol, 19, 599a
- Buchdunger E, 2000, J Pharmacol Exp Ther, 295, 139
- Peng B, 2001, Prog Proc Am Soc Clin Oncol, 20, 71a
Cited by
Items 201–300 of 1,007
The Lessons of GIST—PET and PET/CT: A New Paradigm for Imaging
Van den Abbeele, A. D. (2008) · The Oncologist · doi:10.1634/theoncologist.13-s2-8 · Cited by 292
Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis
Ayala-Aguilera, C. C., Valero, T., Lorente-Macías, Á., Baillache, D. J., Croke, S., & Unciti-Broceta, A. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00963 · Cited by 265
NCCN Guidelines Insights: Kidney Cancer, Version 2.2020
Motzer, R. J., Jonasch, E., Michaelson, M. D., Nandagopal, L., Gore, J. L., George, S., Alva, A., Haas, N., Harrison, M. R., Plimack, E. R., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0054 · Cited by 287
Kilpinen, S., Autio, R., Ojala, K., Iljin, K., Bucher, E., Sara, H., Pisto, T., Saarela, M., Skotheim, R. I., Björkman, M., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r139 · Cited by 283
Liegl, B., Hornick, J. L., Corless, C. L., & Fletcher, C. D. M. (2009) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318186b158 · Cited by 282
Self-citationPatient-centric trials for therapeutic development in precision oncology
Biankin, A. V., Piantadosi, S., & Hollingsworth, S. J. (2015) · Nature · doi:10.1038/nature15819 · Cited by 282
Hawkins, D. S., Schuetze, S. M., Butrynski, J. E., Rajendran, J. G., Vernon, C. B., Conrad, E. U., & Eary, J. F. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.7079 · Cited by 286
(2012) · Annals of Oncology · doi:10.1093/annonc/mds252 · Cited by 281
Van Glabbeke, M., Verweij, J., Casali, P. G., Le Cesne, A., Hohenberger, P., Ray-Coquard, I., Schlemmer, M., van Oosterom, A. T., Goldstein, D., Sciot, R., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.601 · Cited by 280
Skubitz, K. M., & D'Adamo, D. R. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.11.1409 · Cited by 277
Hotte, S. J., Winquist, E. W., Lamont, E., MacKenzie, M., Vokes, E., Chen, E. X., Brown, S., Pond, G. R., Murgo, A., & Siu, L. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.125 · Cited by 278
BRAF targeted therapy changes the treatment paradigm in melanoma
Ribas, A., & Flaherty, K. T. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.69 · Cited by 271
Wyman, K., Atkins, M. B., Prieto, V., Eton, O., McDermott, D. F., Hubbard, F., Byrnes, C., Sanders, K., & Sosman, J. A. (2006) · Cancer · doi:10.1002/cncr.21834 · Cited by 274
Prenen, H., Cools, J., Mentens, N., Folens, C., Sciot, R., Schöffski, P., Van Oosterom, A., Marynen, P., & Debiec-Rychter, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2275 · Cited by 274
Health Effects of the Chernobyl Accident and Special Health Care Programmes
Bennett, B. G., Repacholi, M. H., & Carr, Z. (2006) · Cited by 326
Ghiringhelli, F., Ménard, C., Martin, F., & Zitvogel, L. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00445.x · Cited by 273
Prakash, S., Sarran, L., Socci, N., DeMatteo, R. P., Eisenstat, J., Greco, A. M., Maki, R. G., Wexler, L. H., LaQuaglia, M. P., Besmer, P., et al. (2005) · Journal of Pediatric Hematology/Oncology · doi:10.1097/01.mph.0000157790.81329.47 · Cited by 271
Casali, P. G., Messina, A., Stacchiotti, S., Tamborini, E., Crippa, F., Gronchi, A., Orlandi, R., Ripamonti, C., Spreafico, C., Bertieri, R., et al. (2004) · Cancer · doi:10.1002/cncr.20618 · Cited by 268
The management of metastatic GIST: current standard and investigational therapeutics
Kelly, C. M., Gutierrez Sainz, L., & Chi, P. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01026-6 · Cited by 247
Meier, F. (2005) · Frontiers in Bioscience · doi:10.2741/1755 · Cited by 267
Bauer, S., Duensing, A., Demetri, G. D., & Fletcher, J. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210558 · Cited by 266
Self-citationA conserved protonation-dependent switch controls drug binding in the Abl kinase
Shan, Y., Seeliger, M. A., Eastwood, M. P., Frank, F., Xu, H., Jensen, M. Ø., Dror, R. O., Kuriyan, J., & Shaw, D. E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811223106 · Cited by 262
Surgical Resection of Gastrointestinal Stromal Tumors After Treatment with Imatinib
Andtbacka, R. H. I., Ng, C. S., Scaife, C. L., Cormier, J. N., Hunt, K. K., Pisters, P. W. T., Pollock, R. E., Benjamin, R. S., Burgess, M. A., Chen, L. L., et al. (2006) · Annals of Surgical Oncology · doi:10.1245/s10434-006-9034-8 · Cited by 268
Rutkowski, P., Nowecki, Z. I., Michej, W., Dębiec-Rychter, M., Woźniak, A., Limon, J., Siedlecki, J., Grzesiakowska, U., Kąkol, M., Osuch, C., et al. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9377-9 · Cited by 263
Dancey, J. E., Dobbin, K. K., Groshen, S., Jessup, J. M., Hruszkewycz, A. H., Koehler, M., Parchment, R., Ratain, M. J., Shankar, L. K., Stadler, W. M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2167 · Cited by 258
Effect of St John's wort on imatinib mesylate pharmacokinetics
FRYE, R., FITZGERALD, S., LAGATTUTA, T., HRUSKA, M., & EGORIN, M. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.06.007 · Cited by 258
Oncogenic protein tyrosine kinases: Kit as a human oncogenic tyrosine kinase
Kitamura, Y., & Hirotab, S. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4273-y · Cited by 260
Carlomagno, F., Guida, T., Anaganti, S., Vecchio, G., Fusco, A., Ryan, A. J., Billaud, M., & Santoro, M. (2004) · Oncogene · doi:10.1038/sj.onc.1207810 · Cited by 258
Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure
Pagliarini, R., Shao, W., & Sellers, W. R. (2015) · EMBO reports · doi:10.15252/embr.201439949 · Cited by 253
Targeted therapy in non-small-cell lung cancer—is it becoming a reality?
Janku, F., Stewart, D. J., & Kurzrock, R. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.64 · Cited by 249
Hexner, E. O., Serdikoff, C., Jan, M., Swider, C. R., Robinson, C., Yang, S., Angeles, T., Emerson, S. G., Carroll, M., Ruggeri, B., et al. (2008) · Blood · doi:10.1182/blood-2007-04-083402 · Cited by 252
Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma
Kong, Y., Si, L., Zhu, Y., Xu, X., Corless, C. L., Flaherty, K. T., Li, L., Li, H., Sheng, X., Cui, C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2346 · Cited by 251
Self-citationTarn, C., Rink, L., Merkel, E., Flieder, D., Pathak, H., Koumbi, D., Testa, J. R., Eisenberg, B., von Mehren, M., & Godwin, A. K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803383105 · Cited by 252
Self-citationLe Tourneau, C., Raymond, E., & Faivre, S. (2007) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.2007.3.2.341 · Cited by 247
Congestive heart failure is a rare event in patients receiving imatinib therapy
Atallah, E., Durand, J.-B., Kantarjian, H., & Cortes, J. (2007) · Blood · doi:10.1182/blood-2007-01-070144 · Cited by 252
George, S., Wang, Q., Heinrich, M. C., Corless, C. L., Zhu, M., Butrynski, J. E., Morgan, J. A., Wagner, A. J., Choy, E., Tap, W. D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.9394 · Cited by 248
Self-citationGrowney, J. D., Clark, J. J., Adelsperger, J., Stone, R., Fabbro, D., Griffin, J. D., & Gilliland, D. G. (2005) · Blood · doi:10.1182/blood-2004-12-4617 · Cited by 249
Rutkowski, P., Gronchi, A., Hohenberger, P., Bonvalot, S., Schöffski, P., Bauer, S., Fumagalli, E., Nyckowski, P., Nguyen, B.-P., Kerst, J. M., et al. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3013-7 · Cited by 247
Rock, E. P., Goodman, V., Jiang, J. X., Mahjoob, K., Verbois, S. L., Morse, D., Dagher, R., Justice, R., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-1-107 · Cited by 247
Huang, L., & Roux, B. (2013) · Journal of Chemical Theory and Computation · doi:10.1021/ct4003477 · Cited by 244
Chawla, S. P., Staddon, A. P., Baker, L. H., Schuetze, S. M., Tolcher, A. W., D'Amato, G. Z., Blay, J.-Y., Mita, M. M., Sankhala, K. K., Berk, L., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6329 · Cited by 246
Self-citationSommer, G., Agosti, V., Ehlers, I., Rossi, F., Corbacioglu, S., Farkas, J., Moore, M., Manova, K., Antonescu, C. R., & Besmer, P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1037763100 · Cited by 244
Lack of clinical efficacy of imatinib in metastatic melanoma
Ugurel, S., Hildenbrand, R., Zimpfer, A., La Rosée, P., Paschka, P., Sucker, A., Keikavoussi, P., Becker, J. C., Rittgen, W., Hochhaus, A., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602529 · Cited by 243
Validation of Analytic Methods for Biomarkers Used in Drug Development
Chau, C. H., Rixe, O., McLeod, H., & Figg, W. D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4535 · Cited by 241
Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study
Wheler, J. J., Janku, F., Naing, A., Li, Y., Stephen, B., Zinner, R., Subbiah, V., Fu, S., Karp, D., Falchook, G. S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3043 · Cited by 238
Mohi, M. G., Boulton, C., Gu, T.-L., Sternberg, D. W., Neuberg, D., Griffin, J. D., Gilliland, D. G., & Neel, B. G. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400063101 · Cited by 239
Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease
Kontzias, A., Kotlyar, A., Laurence, A., Changelian, P., & O'Shea, J. J. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.06.008 · Cited by 233
Penel, N., Le Cesne, A., Bui, B. N., Perol, D., Brain, E. G., Ray-Coquard, I., Guillemet, C., Chevreau, C., Cupissol, D., Chabaud, S., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq341 · Cited by 235
Eisenberg, B. L., & Judson, I. (2004) · Annals of Surgical Oncology · doi:10.1245/aso.2004.09.011 · Cited by 236
Self-citationChugh, R., Wathen, J. K., Maki, R. G., Benjamin, R. S., Patel, S. R., Myers, P. A., Priebat, D. A., Reinke, D. K., Thomas, D. G., Keohan, M. L., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.5054 · Cited by 234
Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial
Joensuu, H., Eriksson, M., Sundby Hall, K., Reichardt, A., Hartmann, J. T., Pink, D., Ramadori, G., Hohenberger, P., Al-Batran, S.-E., Schlemmer, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.9170 · Cited by 232
Self-citationThe crucial role of multiomic approach in cancer research and clinically relevant outcomes
Lu, M., & Zhan, X. (2018) · EPMA Journal · doi:10.1007/s13167-018-0128-8 · Cited by 224
Clinical Implications of the Cancer Genome
MacConaill, L. E., & Garraway, L. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4944 · Cited by 229
Imatinib as a Novel Antifibrotic Agent in Bleomycin-induced Pulmonary Fibrosis in Mice
Aono, Y., Nishioka, Y., Inayama, M., Ugai, M., Kishi, J., Uehara, H., Izumi, K., & Sone, S. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-531oc · Cited by 231
Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer
Winter, J. M., Yeo, C. J., & Brody, J. R. (2013) · Journal of Surgical Oncology · doi:10.1002/jso.23192 · Cited by 234
Gastrointestinal stromal tumor
Stamatakos, M., Douzinas, E., Stefanaki, C., Safioleas, P., Polyzou, E., Levidou, G., & Safioleas, M. (2009) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-7-61 · Cited by 221
Chemical approaches to the discovery and development of cancer therapies
Neidle, S., & Thurston, D. E. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1587 · Cited by 224
METABOLISM AND DISPOSITION OF IMATINIB MESYLATE IN HEALTHY VOLUNTEERS
Gschwind, H.-P., Pfaar, U., Waldmeier, F., Zollinger, M., Sayer, C., Zbinden, P., Hayes, M., Pokorny, R., Seiberling, M., Ben-Am, M., et al. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.004283 · Cited by 223
Self-citationOtani, Y., Furukawa, T., Yoshida, M., Saikawa, Y., Wada, N., Ueda, M., Kubota, T., Mukai, M., Kameyama, K., Sugino, Y., et al. (2006) · Surgery · doi:10.1016/j.surg.2005.08.011 · Cited by 224
Phase I Trial Design for Solid Tumor Studies of Targeted, Non-Cytotoxic Agents: Theory and Practice
Parulekar, W. R., & Eisenhauer, E. A. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh182 · Cited by 223
Prevalence of KIT Expression in Human Tumors
Went, P. T., Dirnhofer, S., Bundi, M., Mirlacher, M., Schraml, P., Mangialaio, S., Dimitrijevic, S., Kononen, J., Lugli, A., Simon, R., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.125 · Cited by 222
Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders
Pardanani, A., Reeder, T., Porrata, L. F., Li, C.-Y., Tazelaar, H. D., Baxter, E. J., Witzig, T. E., Cross, N. C. P., & Tefferi, A. (2003) · Blood · doi:10.1182/blood-2002-10-3103 · Cited by 227
Differential effects of JNK1 and JNK2 inhibition on murine steatohepatitis and insulin resistance†
Singh, R., Wang, Y., Xiang, Y., Tanaka, K. E., Gaarde, W. A., & Czaja, M. J. (2009) · Hepatology · doi:10.1002/hep.22578 · Cited by 223
Kinase inhibitors and monoclonal antibodies in oncology: clinical implications
Gharwan, H., & Groninger, H. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.213 · Cited by 224
Gastrointestinal stromal tumor: 5 years later
van der Zwan, S. M., & DeMatteo, R. P. (2005) · Cancer · doi:10.1002/cncr.21419 · Cited by 218
Zhang, L., Smyrk, T. C., Young, W. F., Stratakis, C. A., & Carney, J. A. (2010) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181c20f4f · Cited by 221
Seeliger, M. A., Nagar, B., Frank, F., Cao, X., Henderson, M. N., & Kuriyan, J. (2007) · Structure · doi:10.1016/j.str.2007.01.015 · Cited by 221
Progress in tuberculosis vaccine development and host-directed therapies—a state of the art review
Kaufmann, S. H. E., Lange, C., Rao, M., Balaji, K. N., Lotze, M., Schito, M., Zumla, A. I., & Maeurer, M. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70033-5 · Cited by 217
New clinical trial design in precision medicine: discovery, development and direction
Duan, X.-P., Qin, B.-D., Jiao, X.-D., Liu, K., Wang, Z., & Zang, Y.-S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01760-0 · Cited by 197
Challenging issues in pediatric oncology
Pui, C.-H., Gajjar, A. J., Kane, J. R., Qaddoumi, I. A., & Pappo, A. S. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.95 · Cited by 217
EUS-guided sampling of suspected GI stromal tumors
Hoda, K. M., Rodriguez, S. A., & Faigel, D. O. (2009) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2008.09.045 · Cited by 203
Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis
Paniagua, R. T. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28546 · Cited by 220
Cools, J., Stover, E. H., Boulton, C. L., Gotlib, J., Legare, R. D., Amaral, S. M., Curley, D. P., Duclos, N., Rowan, R., Kutok, J. L., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00108-9 · Cited by 216
Ilic, N., Utermark, T., Widlund, H. R., & Roberts, T. M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108237108 · Cited by 211
Gastrointestinal stromal tumors: CT and MRI findings
Sandrasegaran, K., Rajesh, A., Rushing, D. A., Rydberg, J., Akisik, F. M., & Henley, J. D. (2005) · European Radiology · doi:10.1007/s00330-005-2647-7 · Cited by 215
A precision therapy against cancers driven by KIT/PDGFRA mutations
Evans, E. K., Gardino, A. K., Kim, J. L., Hodous, B. L., Shutes, A., Davis, A., Zhu, X. J., Schmidt-Kittler, O., Wilson, D., Wilson, K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aao1690 · Cited by 206
Self-citationPoly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic
Yap, T. A., Sandhu, S. K., Carden, C. P., & de Bono, J. S. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20095 · Cited by 208
Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma
Motzer, R. J., Bukowski, R. M., Figlin, R. A., Hutson, T. E., Michaelson, M. D., Kim, S. T., Baum, C. M., & Kattan, M. W. (2008) · Cancer · doi:10.1002/cncr.23776 · Cited by 211
Nacev, B. A., Jones, K. B., Intlekofer, A. M., Yu, J. S. E., Allis, C. D., Tap, W. D., Ladanyi, M., & Nielsen, T. O. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0288-4 · Cited by 209
Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity
Debiec‐Rychter, M., Wasag, B., Stul, M., De Wever, I., Van Oosterom, A., Hagemeijer, A., & Sciot, R. (2004) · The Journal of Pathology · doi:10.1002/path.1546 · Cited by 213
Heinrich, M. C., Joensuu, H., Demetri, G. D., Corless, C. L., Apperley, J., Fletcher, J. A., Soulieres, D., Dirnhofer, S., Harlow, A., Town, A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4575 · Cited by 213
Self-citationAbsence of BRAF and NRAS mutations in uveal melanoma.
Cruz, F., Rubin, B. P., Wilson, D. J., Town, A., Schroeder, A., Haley, A., Bainbridge, T., Heinrich, M. C., & Corless, C. L. (2003) · PubMed · Cited by 208
Self-citationWang, D., Zhang, Q., Blanke, C. D., Demetri, G. D., Heinrich, M. C., Watson, J. C., Hoffman, J. P., Okuno, S., Kane, J. M., von Mehren, M., et al. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-011-2190-5 · Cited by 204
Self-citationPIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers
Janku, F., Lee, J. J., Tsimberidou, A. M., Hong, D. S., Naing, A., Falchook, G. S., Fu, S., Luthra, R., Garrido-Laguna, I., & Kurzrock, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022769 · Cited by 204
Cancer Genomics: Diversity and Disparity Across Ethnicity and Geography
Tan, D. S. W., Mok, T. S. K., & Rebbeck, T. R. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.0096 · Cited by 202
Rosée, P. G. L., Corbin, A. S., Stoffregen, E. P., Deininger, M. W., & Druker, B. J. (2002) · PubMed · Cited by 225
Self-citationActivation of Abl Tyrosine Kinases Promotes Invasion of Aggressive Breast Cancer Cells
Srinivasan, D., & Plattner, R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0734 · Cited by 203
Su, H., Bodenstein, C., Dumont, R. A., Seimbille, Y., Dubinett, S., Phelps, M. E., Herschman, H., Czernin, J., & Weber, W. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0368 · Cited by 202
Prevalence and detection of low-allele-fraction variants in clinical cancer samples
Shin, H.-T., Choi, Y.-L., Yun, J. W., Kim, N. K. D., Kim, S.-Y., Jeon, H. J., Nam, J.-Y., Lee, C., Ryu, D., Kim, S. C., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01470-y · Cited by 203
Wu, Q., Qian, W., Sun, X., & Jiang, S. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01362-9 · Cited by 200
Levis, M., Brown, P., Smith, B. D., Stine, A., Pham, R., Stone, R., DeAngelo, D., Galinsky, I., Giles, F., Estey, E., et al. (2006) · Blood · doi:10.1182/blood-2006-04-015743 · Cited by 199
O'Hare, T., Pollock, R., Stoffregen, E. P., Keats, J. A., Abdullah, O. M., Moseson, E. M., Rivera, V. M., Tang, H., Metcalf, C. A., Bohacek, R. S., et al. (2004) · Blood · doi:10.1182/blood-2004-05-1851 · Cited by 200
Self-citationCurrent Trends in Targeted Therapies for Glioblastoma Multiforme
Ohka, F., Natsume, A., & Wakabayashi, T. (2012) · Neurology Research International · doi:10.1155/2012/878425 · Cited by 200
Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome
Griffin, J. H., Leung, J., Bruner, R. J., Caligiuri, M. A., & Briesewitz, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932698100 · Cited by 202
Gastrointestinal stromal tumours: an update
Rubin, B. P. (2006) · Histopathology · doi:10.1111/j.1365-2559.2005.02291.x · Cited by 200
Haouala, A., Zanolari, B., Rochat, B., Montemurro, M., Zaman, K., Duchosal, M. A., Ris, H. B., Leyvraz, S., Widmer, N., & Decosterd, L. A. (2009) · Journal of Chromatography B · doi:10.1016/j.jchromb.2009.04.045 · Cited by 200
Casali, P. G., Zalcberg, J., Le Cesne, A., Reichardt, P., Blay, J.-Y., Lindner, L. H., Judson, I. R., Schöffski, P., Leyvraz, S., Italiano, A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.0228 · Cited by 194
Measuring and interpreting the selectivity of protein kinase inhibitors
Smyth, L. A., & Collins, I. (2009) · Journal of Chemical Biology · doi:10.1007/s12154-009-0023-9 · Cited by 197
Sihto, H., Sarlomo-Rikala, M., Tynninen, O., Tanner, M., Andersson, L. C., Franssila, K., Nupponen, N. N., & Joensuu, H. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.093 · Cited by 196
Self-citationLassau, N., Lamuraglia, M., Chami, L., Leclère, J., Bonvalot, S., Terrier, P., Roche, A., & Le Cesne, A. (2006) · American Journal of Roentgenology · doi:10.2214/ajr.05.1192 · Cited by 196
Metadata
- Authors
- Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., Fletcher, J. A., Silverman, S. G., Silberman, S. L., Capdeville, R., Kiese, B., Peng, B., Dimitrijevic, S., Druker, B. J., Corless, C., Fletcher, C. D. M., & Joensuu, H.
- Affiliations
- Harvard University (US)
- Oregon Health & Science University (US)
- Fox Chase Cancer Center (US)
- Novartis (Switzerland) (CH)
- University of Helsinki (FI)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-08-15
- Volume
- 347
- Issue
- 7
- Pages
- 472-480
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2015015957
- Cited by
- 4,389
- References
- 21
- Citations by year
- 2026: 85 · 2025: 91 · 2024: 107 · 2023: 115 · 2022: 117 · 2021: 128 · 2020: 136 · 2019: 119 · 2018: 131 · 2017: 136 · 2016: 160 · 2015: 182 · 2014: 192 · 2013: 210 · 2012: 255
- FWCI
- 167.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- CRC Press eBooks (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- U.S. Department of Veterans Affairs
- Northwest Health Foundation
- Helsingin Yliopisto
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal Tumor Research and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Keywords
- imatinib mesylate, gastrointestinal stromal tumor, KIT receptor tyrosine kinase, tyrosine kinase inhibitors, antitumor immunity, drug resistance, pharmacokinetics, adverse effects, metastatic cancer, dose comparison
- MeSH terms
- Imatinib Mesylate, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Benzamides, Female, Gastrointestinal Neoplasms, Humans, Male, Middle Aged, Piperazines, Protein-Tyrosine Kinases, Pyrimidines, Remission Induction, Signal Transduction, Survival Analysis, Stromal Cells, Proto-Oncogene Proteins c-kit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.